Cargando…
Immunotherapy for Pemphigus: Present and Future
Pemphigus is a chronic and severe autoimmune bullous disease caused by autoantibodies targeting adhesion molecules between keratinocytes. It requires 2–3 years on average to manage the disease. To date, although Rituximab combined with short-term systemic glucocorticoids was accepted as first-line t...
Autores principales: | Yuan, Huijie, Pan, Meng, Chen, Hongxiang, Mao, Xuming |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9240651/ https://www.ncbi.nlm.nih.gov/pubmed/35783635 http://dx.doi.org/10.3389/fmed.2022.901239 |
Ejemplares similares
-
Pemphigus Vulgaris: Present and Future Therapeutic Strategies
por: Didona, Dario, et al.
Publicado: (2022) -
The Genetics of Pemphigus Vulgaris
por: Vodo, Dan, et al.
Publicado: (2018) -
Successful treatment with thalidomide for pemphigus vulgaris
por: Zhang, Bingjie, et al.
Publicado: (2020) -
Autoantibody-Specific Signalling in Pemphigus
por: Schmitt, Thomas, et al.
Publicado: (2021) -
Case report: Mounded and refractory keratoses (MARK), a novel presentation of pemphigus vulgaris
por: Le, Stephanie T., et al.
Publicado: (2023)